Drugs / Oral Polio Vaccine
Oral Polio Vaccine
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 32 trials | ||||||
| Phase 3 | NCT04540185 | Nov 2020 → Nov 2022 | COVID-19, severe acute respiratory syndrome | Biomed Industries, Inc. | Unknown | No outcome recorded |
| Phase 3 | NCT03581734 | Jul 2018 → Oct 2022 | vaccinia | International Centre for Diarrhoeal Disease Research, Bangladesh | Unknown | No outcome recorded |
| Phase 45 trials · 1 met primary · 1 missed | ||||||
| Phase 4 | NCT06266754 | Jan → Jul 2024 | vaccinia | Bandim Health Project | Unknown | No outcome recorded |
| Phase 4 | NCT04445428 | Jul 2020 → Jan 2022 | COVID-19, poliomyelitis | Bandim Health Project | Completed | Missed primary |
| Phase 4 | NCT03460002 | Nov 2016 → Oct 2021 | measles | Bandim Health Project | Completed | No outcome recorded |
| Phase 4 | NCT02580201 | Nov 2015 → Jul 2016 | poliomyelitis | Fidec Corporation | Completed | No outcome recorded |
| Phase 4 | NCT01908114 | Jul 2013 → Jul 2017 | poliomyelitis | Aga Khan University | Unknown | Met primary |
| Comparator or background therapy5 trials | ||||||
| Phase 3 | NCT00514709 Background | Sep 2007 → Dec 2008 | diphtheria, hepatitis B virus infection, influenza, pertussis +1 | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT00534833 Background | Sep 2007 → Sep 2008 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, pertussis +1 | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT00343889 Background | Aug 2006 → Nov 2007 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, pertussis +1 | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 4 | NCT01616693 Background | Jul 2012 → Jul 2013 | — | PATH | Completed | Met primary |
| — | NCT00710983 Comparator | Jul 2008 → Jun 2014 | — | Bandim Health Project | Unknown | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Oral Polio Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02580201 ↗ |
| Known as | Bivalent OPV (GSK) | “Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump” NCT04540185 ↗ |
| Known as | bOPV | “Bivalent oral polio vaccine (bOPV)” NCT03581734 ↗ |
| Known as | OPV | “Study on the Immunogenicity of Oral Polio Vaccine (OPV) and Oral Cholera Vaccine (OCV) When Co-administered” NCT03581734 ↗5“OPV given at birth (OPV0) was associated with increased male infant mortality” PMID 26219694 ↗ Jul 2015 “Oral polio vaccine (OPV) may improve resistance to non-polio-infections.” PMID 36193229 ↗ Sep 2022 “OPV is the live attenuated vaccine against polio virus.” NCT06266754 ↗ “Oral Polio Vaccine (OPV)” NCT00343889 ↗ “Oral Polio Vaccine (OPV)” NCT00534833 ↗ |
| Known as | OPV0 | “OPV given at birth (OPV0) was associated with increased male infant mortality” PMID 26219694 ↗ Jul 2015 |
| Known as | Opvero | “Opvero™ (oral) is a trivalent, live attenuated poliomyelitis virus vaccine containing at least 6.0 log 50% cell culture infective dose (CCID50) of LS c2ab strain of live...” NCT02580201 ↗ |
| Known as | Oral Polio Vaccine (OPV) | “Oral Polio Vaccine (OPV)” NCT04540185 ↗ |
| Modality | Vaccine | “Oral Polio Vaccine” NCT00343889 ↗ |
| Route | Oral | “Oral co-administered with study vaccine” NCT00343889 ↗ |